+

WO2002032452A1 - Medicament pour le traitement du sida et son procede de preparation - Google Patents

Medicament pour le traitement du sida et son procede de preparation Download PDF

Info

Publication number
WO2002032452A1
WO2002032452A1 PCT/CN2001/001192 CN0101192W WO0232452A1 WO 2002032452 A1 WO2002032452 A1 WO 2002032452A1 CN 0101192 W CN0101192 W CN 0101192W WO 0232452 A1 WO0232452 A1 WO 0232452A1
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
eldkwa
treating aids
variant
monoclonal antibody
Prior art date
Application number
PCT/CN2001/001192
Other languages
English (en)
Chinese (zh)
Inventor
Yinghua Chen
Yi Xiao
Haijun Tian
Original Assignee
Tsinghua University
Chinatex Industry Development Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Chinatex Industry Development Corp. filed Critical Tsinghua University
Priority to AU2002214920A priority Critical patent/AU2002214920A1/en
Publication of WO2002032452A1 publication Critical patent/WO2002032452A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to a medicament for treating AIDS prepared by bioengineering technology and a method for preparing the same, in particular to a medicament for treating AIDS prepared by using a monoclonal antibody against HIV membrane protein and a preparation method thereof.
  • the disease also known as acquired immunodeficiency syndrome, is an immune disease caused by the human immunodeficiency virus (HIV). Because of its rapid spread and extremely high mortality, there are no specific treatments, and no vaccine can prevent it.
  • HIV human immunodeficiency virus
  • the object of the present invention is to provide an effective medicine for treating AIDS, which medicine can deal with the mutation of the HIV virus.
  • Another object of the present invention is to provide a method for preparing the above medicament for treating AIDS.
  • the present invention adopts the following design scheme: A drug for treating AIDS, which basically includes at least one monoclonal antibody whose antigen is the ELDKWA epitope on human immunodeficiency virus transmembrane protein gp41 and Its variant epitope.
  • the variant epitope is ELEKWA, ELNKWA or ELDEWA.
  • the medicine for treating AIDS of the present invention preferably consists of the following components:
  • ELDKWA epidermal-specific monoclonal antibody
  • ELEKWA epidermal-specific monoclonal antibody
  • a method for preparing the above medicament for treating AIDS basically includes the following steps: (1) artificially synthesizing at least one epitope polypeptide containing a neutralizing epitope on human immunodeficiency virus transmembrane protein gp41, and the neutralizing The epitope is selected from the ELDKWA epitope or / and its variant epitope or at least one repeating ELDKWA epitope or / and its variant epitope;
  • the at least one artificially synthesized polypeptide is preferably: at least one repeated neutralizing epitope ELDKWA or its variant epitope on human immunodeficiency virus transmembrane protein gp41, respectively.
  • the variant epitope of the ELDKWA epitope is ELEKWA, ELNKWA or ELDEWA.
  • the medicine for treating AIDS of the present invention is a medicine containing various antibodies against the main neutralizing epitope ELDKWA epitope on human immunodeficiency virus transmembrane protein gp41 and its variant epitopes (such as ELEKWA, ELNKWA, ELDEWA), even in AIDS
  • ELDKWA epitope on human immunodeficiency virus transmembrane protein gp41
  • its variant epitopes such as ELEKWA, ELNKWA, ELDEWA
  • the medicament of the invention is not only non-toxic, but also can reduce the cost of AIDS treatment while improving the effect of AIDS immunotherapy.
  • the invention adopts a method of artificially synthesizing epitope polypeptide to induce and prepare a predetermined monoclonal antibody specific for an epitope, which overcomes the need to immunize with a natural protein or a recombinant protein, and then performs a large number of screening and identification to obtain the predetermined epitope specificity.
  • Sexual monoclonal antibodies perform many complex tasks.
  • the corresponding type of medicine can be produced quickly according to the mutation of the HIV virus, without the need for long-term tests, and the production cost can be reduced.
  • This technology will have a significant impact on the world's preventive medicine research and will bring huge economic and social benefits.
  • Example 1 A medicament for treating AIDS made from a neutralized epitope ELDKWA on HIV-1 gp41, a variant epitope ELNKWA-epitope-specific antibody as a main active ingredient, produced by the following steps:
  • the dosage of the drug in actual application is determined according to the patient's condition.
  • Example 2 From neutralizing epitope ELDKWA and its variant epitope ELNKWA on anti-HIV-1 g p4l,
  • Antibodies to ELEKWA and ELDEWA are the main active ingredients for the treatment of AIDS. They are produced by the following steps-(1), artificial synthesis of 4 human immunodeficiency virus transmembrane protein gp4l neutralizing epitopes ELDKWA and its variants.
  • Epitope ELNKWA, ELEKWA or ELDEWA polypeptide are produced by the following steps-(1), artificial synthesis of 4 human immunodeficiency virus transmembrane protein gp4l neutralizing epitopes ELDKWA and its variants.
  • the mutation of HIV can be obviously resisted, the load of HIV can be reduced, the progress of the disease can be delayed, and finally the purpose of cure is achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un médicament pour le traitement du sida et son procédé de préparation. Ledit médicament renferme essentiellement au moins un anticorps monoclonal dont l'antigène provient des épitopes de neutralisation ELDKWA se trouvant sur la protéine transmembranaire gp41 du virus de l'immunodéficience humaine et de ses variantes qui sont ELEKWA, ELNKWA et ELDEWA F. Le procédé de préparation du médicament de cette invention consiste à 1) synthétiser artificiellement au moins un épitope de neutralisation ELDKWA se trouvant sur la protéine transmembranaire gp41 du virus de l'immunodéficience humaine et/ou ses variantes ; 2) lier des polypeptides aux protéines porteuses correspondantes ou aux polypeptides porteurs ; 3) immuniser des animaux à l'aide de ces conjugués ; 4) préparer des hybridomes ; et 5) combiner les quatre groupes d'anticorps obtenus afin d'obtenir le médicament faisant l'objet de cette invention.
PCT/CN2001/001192 2000-08-18 2001-07-20 Medicament pour le traitement du sida et son procede de preparation WO2002032452A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214920A AU2002214920A1 (en) 2000-08-18 2001-07-20 Composition for aids and method producing it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001234838A CN1172717C (zh) 2000-08-18 2000-08-18 一种治疗艾滋病的药物及其制备方法
CN00123483.8 2000-08-18

Publications (1)

Publication Number Publication Date
WO2002032452A1 true WO2002032452A1 (fr) 2002-04-25

Family

ID=4589903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001192 WO2002032452A1 (fr) 2000-08-18 2001-07-20 Medicament pour le traitement du sida et son procede de preparation

Country Status (3)

Country Link
CN (1) CN1172717C (fr)
AU (1) AU2002214920A1 (fr)
WO (1) WO2002032452A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093985A1 (fr) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Agents de liaison au vih
WO2020012435A1 (fr) 2018-07-13 2020-01-16 Lausanne University Hospital Agents de liaison au vih
WO2021009697A2 (fr) 2019-07-15 2021-01-21 Lausanne University Hospital Agents de liaison au vih

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500248C (fr) * 2002-09-24 2013-03-19 Frontier Biotechnologies Co., Ltd. Inhibiteurs de fusion contre l'infection au vih derives de peptides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492560A2 (fr) * 1990-12-26 1992-07-01 Joseph P. Cotropia Anticorps monoclonaux humains contre la glycoprotéine transmembranaire (gp41) de HIV-1, et peptides associés
WO1994012533A1 (fr) * 1992-11-23 1994-06-09 President And Fellows Of Harvard College Gp41 mutants et leur utilisation comme agents therapeutiques contre le vih
WO1994029339A1 (fr) * 1993-06-09 1994-12-22 Connaught Laboratories Limited Peptides synthetiques en tandem contre le vih-1
WO1995001993A1 (fr) * 1993-07-06 1995-01-19 University Of Utah Research Foundation COMPOSES AYANT L'ANTIGENICITE DE hCG
WO1995007354A1 (fr) * 1993-09-11 1995-03-16 Polymun Scientific Immunobiologische Forschung Gmbh Peptides qui produisent des anticorps neutralisants contre des souches de vih-1 genetiquement divergentes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492560A2 (fr) * 1990-12-26 1992-07-01 Joseph P. Cotropia Anticorps monoclonaux humains contre la glycoprotéine transmembranaire (gp41) de HIV-1, et peptides associés
WO1994012533A1 (fr) * 1992-11-23 1994-06-09 President And Fellows Of Harvard College Gp41 mutants et leur utilisation comme agents therapeutiques contre le vih
WO1994029339A1 (fr) * 1993-06-09 1994-12-22 Connaught Laboratories Limited Peptides synthetiques en tandem contre le vih-1
WO1995001993A1 (fr) * 1993-07-06 1995-01-19 University Of Utah Research Foundation COMPOSES AYANT L'ANTIGENICITE DE hCG
WO1995007354A1 (fr) * 1993-09-11 1995-03-16 Polymun Scientific Immunobiologische Forschung Gmbh Peptides qui produisent des anticorps neutralisants contre des souches de vih-1 genetiquement divergentes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093985A1 (fr) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Agents de liaison au vih
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
WO2020012435A1 (fr) 2018-07-13 2020-01-16 Lausanne University Hospital Agents de liaison au vih
WO2021009697A2 (fr) 2019-07-15 2021-01-21 Lausanne University Hospital Agents de liaison au vih

Also Published As

Publication number Publication date
CN1172717C (zh) 2004-10-27
AU2002214920A1 (en) 2002-04-29
CN1339318A (zh) 2002-03-13

Similar Documents

Publication Publication Date Title
Zhang et al. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
CA2218515C (fr) Anticorps monoclonaux contre vih 1 et vaccins en decoulant
US5922325A (en) Synergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the v3 loop and the CD-4 binding site of GP-120,and the use for immunotherapy of HIV-1 infection
AT398080B (de) Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel
US20030003440A1 (en) Novel CCR5 epitope and antibodies against it
EP0939835A1 (fr) Compositions et procedes destines au traitement d'infections virales
Gorny et al. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins
JPH07506810A (ja) 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用
CN103179987A (zh) 抑制p24蛋白产生或促进p24蛋白消除的方法和药物组合物
US6268484B1 (en) HIV-vaccines
DE69527708T2 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
Stein et al. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual
WO2002032452A1 (fr) Medicament pour le traitement du sida et son procede de preparation
He et al. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120–CD4 complex in transgenic mice that produce human immunoglobulins
Mohan et al. Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides
EP0719281A1 (fr) Constructions de peptides a branches multiples destines a etre utilises contre le vih
WO2002026259A1 (fr) Medicament pour le traitement du sida et son procede de preparation
CN107224578B (zh) Hiv疫苗及其制备方法
WO2002026253A1 (fr) Vaccin contre le sida, son procede de preparation et ses applications
RU2006129097A (ru) Новые тат-комплексы и включающие их вакцины
US20110293697A1 (en) HIV-1 Immunogenic Compositions
US10280213B2 (en) Broadly cross-reactive HIV-1 Env-specific antibodies
EP0370090A1 (fr) Immunogenes et peptides biologiquement actifs derives de sequences partagees d'antigenes et d'anticorps anti-idiotypiques ou d'anticorps specifiques contre des recepteurs cellulaires des antigenes.
Mu Design and Immunogenicity of Stabilized HIV-1 Modified Messenger RNA Vaccines
JPH08198774A (ja) Ｄｎａワクチン

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载